Last reviewed · How we verify
Clomiphene Citrate 50 mg
At a glance
| Generic name | Clomiphene Citrate 50 mg |
|---|---|
| Sponsor | EMD Serono |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Headache
- Adnexa uteri pain
- Nausea
- Back pain
- Hot flush
- Breast tenderness
Key clinical trials
- INTEnsity of ovariaN Stimulation and Embryo Quality (PHASE4)
- Sex Hormone Supplementation and Rotator Cuff Repair: A Preliminary Randomized Trial (PHASE2)
- The Effect Of Polycystic Ovarian Syndrome Treatment On Ocular Surface.
- Ovarian Hyperstimulation and Fibrin Clot Properties. (NA)
- Interest of Clomiphene Citrate in Patients With Non-obstructive Azoospermia on the Quantity of Sperm Cells (PHASE3)
- Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation (PHASE4)
- Study of Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Medicinal Product MediReg® (PHASE1, PHASE2)
- Pharmacokinetic Evaluation of Serum Testosterone Concentrations After Administration of Clomiphene Citrate (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clomiphene Citrate 50 mg CI brief — competitive landscape report
- Clomiphene Citrate 50 mg updates RSS · CI watch RSS
- EMD Serono portfolio CI